Literature DB >> 11170288

BRCA2 mutation in a family with hereditary prostate cancer.

H Grönberg1, A K Ahman, M Emanuelsson, A Bergh, J E Damber, A Borg .   

Abstract

Hereditary prostate cancer is a genetically heterogeneous disease, and so far four different susceptibility loci have been identified. Reports of associated cancers are few, and it is generally considered a site-specific disease. However, some reports have shown an elevated risk for prostate cancer among BRCA2 mutation carriers. In this report, we present a family in which the father and four of his sons were diagnosed with prostate cancer at exceptionally early ages (51, 52, 56, 58, and 63 years, respectively). In addition, three daughters were diagnosed with breast cancer between the ages of 47 and 61. In this family, a truncating mutation in exon 11, 6051delA of the BRCA2 gene, leading to an early termination of the protein (codon 1962), was identified. Although BRCA2 is probably responsible only for a very small fraction of hereditary prostate cancers, this finding supports previous reports of an increased risk of prostate cancer in BRCA2 mutation carriers. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170288

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Authors:  S M Edwards; D G R Evans; Q Hope; A R Norman; Y Barbachano; S Bullock; Z Kote-Jarai; J Meitz; A Falconer; P Osin; C Fisher; M Guy; S G Jhavar; A L Hall; L T O'Brien; B N Gehr-Swain; R A Wilkinson; M S Forrest; D P Dearnaley; A T Ardern-Jones; E C Page; D F Easton; R A Eeles
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

2.  Familial prostate cancer: the damage done and lessons learnt.

Authors:  Nassim Taherian; Nancy Hamel; Louis R Bégin; Tarek A Bismar; David E Goldgar; Bing-Jian Feng; William D Foulkes
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

3.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

4.  The clinical genetics of prostate cancer.

Authors:  Sashi Kommu; Stephen Edwards; Rosalind Eeles
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

5.  Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.

Authors:  A Mitra; C Fisher; C S Foster; C Jameson; Y Barbachanno; J Bartlett; E Bancroft; R Doherty; Z Kote-Jarai; S Peock; D Easton; R Eeles
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

Review 6.  Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.

Authors:  Shyh-Han Tan; Gyorgy Petrovics; Shiv Srivastava
Journal:  Int J Mol Sci       Date:  2018-04-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.